Hims & Hers Health (NYSE:HIMS) Insider Deborah Autor Sells 16,773 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Deborah Autor sold 16,773 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total value of $467,128.05. Following the completion of the transaction, the insider owned 48,961 shares of the company’s stock, valued at approximately $1,363,563.85. This represents a 25.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Stock Up 2.8%

Shares of NYSE:HIMS opened at $31.95 on Friday. The company has a market capitalization of $7.45 billion, a price-to-earnings ratio of -50.71 and a beta of 2.40. The company has a 50 day moving average of $32.23 and a two-hundred day moving average of $26.09. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $65.30. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.17 earnings per share. As a group, analysts forecast that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current fiscal year.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum defended Hims & Hers against the FTC’s allegations and said the company’s strategy could improve patient access and affordability. He also discussed a potential AI health coach that could support medication adherence, creating a possible long-term technology catalyst. Hims & Hers rejects privacy allegations
• Positive Sentiment: Some investors continue to view the recent margin weakness as an opportunity, citing Hims & Hers’ 38.2% year-over-year revenue growth and potential expansion into testosterone, peptides, branded GLP-1 treatments and international markets. However, execution and profitability remain important hurdles. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Recent insider filings show sales by CFO Oluyemi Okupe, Deborah M. Autor and Soleil Boughton. The transactions were conducted under pre-arranged Rule 10b5-1 plans, and several sales were intended to cover tax obligations from vested equity awards. Because insiders retained substantial positions, the filings are a limited bearish signal rather than clear evidence of weakening confidence. SEC insider transaction filing
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” while Needham raised its price target to $42 and maintained a Buy rating. The split view reflects strong sales growth but concerns about losses, margins and the GLP-1 business strategy.
• Negative Sentiment: The FTC litigation and new investigations by Kaplan Fox and Berger Montague add potential legal costs, compliance requirements and reputational risk. The investigations focus on alleged sharing of private health data, deceptive billing and difficult subscription cancellations, keeping regulatory uncertainty over the stock. Kaplan Fox investigation
• Negative Sentiment: Hims & Hers’ latest quarter showed a larger-than-expected loss of $0.37 per share versus the $0.05 consensus estimate, despite revenue exceeding expectations. The earnings miss and negative profitability metrics could limit the stock’s upside until margins improve.

Analyst Ratings Changes

A number of analysts have recently issued reports on HIMS shares. JPMorgan Chase & Co. dropped their target price on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. UBS Group set a $23.00 target price on Hims & Hers Health in a research note on Friday, May 22nd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus target price of $32.43.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc raised its stake in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after buying an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares in the last quarter. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $28,000. Bogart Wealth LLC increased its holdings in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the 1st quarter valued at approximately $30,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.